BioServe Biotechnologies, Ltd. agreed to acquire Stemgent Inc. and Biopta Inc. from Biopta Ltd and ReproCELL, Inc. (JASDAQ:4978) on August 1, 2016. Under the terms of the transaction, after the completion of the transaction, Bioserve will be the surviving company and Stemgent Inc. and Biopta Inc. will be dissolved. Bioserve Biotehnologies, Ltd. will change company name into ReproCELL U.S.A. Inc., and ReproCell will hold 92.55 percent stake in ReproCELL U.S.A. The transaction will be effective from September 1, 2016. BioServe Biotechnologies, Ltd. cancelled the acquisition of Stemgent Inc. and Biopta Inc. from Biopta Ltd and ReproCELL, Inc. (JASDAQ:4978) on August 1, 2017.